LC
ACUR

Lincoln Capital’s Acura Pharmaceuticals ACUR Stock Holding History

Lincoln Capital’s Portfolio ACUR Stock Details ACUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-4,200
Closed -$21K – 62
2015
Q2 		$21K Hold
4,200
– – 0.02% 57
2015
Q1 		$17K Hold
4,200
– – 0.01% 57
2014
Q4 		$9K Buy
+4,200
New +$11.6K 0.01% 55

Other funds holding ACUR

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.61B AUM 19.97% 1-Year Est. Return

Lincoln Capital's ACUR Position: Q3 2015 in Review

Lincoln Capital sold out of Acura Pharmaceuticals (ACUR) in Q3 2015, closing a stake of 4,200 shares — an estimated $21K sold.

Lincoln Capital first reported a position in ACUR in Q4 2014 and held it in 3 quarters. The position peaked at $21K in Q2 2015. 22 funds tracked by Wall St. Rank hold ACUR as of Q3 2015.

  • Lincoln Capital reported no remaining Acura Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Lincoln Capital sold 4,200 Acura Pharmaceuticals shares in Q3 2015, an estimated $21K.
  • Lincoln Capital first reported a position in Acura Pharmaceuticals in Q4 2014 and held it in 3 quarters.
  • Lincoln Capital's Acura Pharmaceuticals position peaked at $21K in Q2 2015.
  • 22 funds tracked by Wall St. Rank held Acura Pharmaceuticals as of Q3 2015.

Based on Lincoln Capital's 13F filing for Q3 2015, filed 20 Oct 2015.